Realm Therapeutics unveils phase II failure of PR022 for severe eczema
US-based Realm Therapeutics has announced its drug candidate PR022 for atopic dermatitis has failed to achieve its primary endpoint in...
Trending:
-
![HIV-1]()
Janssen and ViiV report positive results for two drug regimen for HIV-1
-
![nusinersen]()
NICE does not recommend NHS use of Biogen’s nusinersen for SMA
-
![remifentanil]()
Study shows remifentanil better at relieving pain in labour than current standard care
-
![]()
Big soil: Genentech and Lodo launch $1bn project to develop new drugs from earth
-
![PhRMA survey]()
PhRMA survey shows US biopharma exceeded R&D spending record in 2017
-
![Natural Cycles]()
FDA approves first direct-to-consumer contraceptive app Natural Cycles
Expert commentary & analysis from GlobalData
EMA gives PRIME status to promising Huntington’s treatment
UK seeks harmony with EU CTR as NHS and pharma stockpile drugs
The road to market: breaking down the stages of clinical trials for pharmaceutical products
Pfizer/Lilly’s Phase III trial for tanezumab in osteoarthritis still draws caution
Most Read
Company releases
Join NSF at 78th FIP World Congress of Pharmacy and Pharmaceutical Sciences, Glasgow
NSF will be exhibiting at the 2018 International Pharmaceutical Federation (FIP) World Congress in Glasgow, Scotland.
New Strategies to Promote Compliance and Inspection Readiness
NextGenAAV
SIRION Biotech offers full customisation services for gene therapy research and development (R&D). The company optimises adeno-associated virus (AAV) tissue...
Gerresheimer at Medtec China
Adenovirus
SIRION Biotech’s engineered adenovirus vectors are used for transient and quantitative gene expression or knockdown.
Company whitepapers
Getting to the Bottom of Data Integrity: Four to Explore
NSF International, Pharma BiotechFast and Reliable Quantification of Data
Malvern PanalyticalGT X.ONE – Excellence in Granulation Technology
ACG Associated CapsulesPatch Pump Applications
Weibel CDSNinconex Medical Brochure
Niconex MedicalPharmaceutical Challenges Aided by Laboratory Powder X-ray Diffraction
Malvern PanalyticalThe Secrets of Efficient Combination Product Development
anteris medicalCompany A-Z
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Projects
Amgen’s New Bio-manufacturing Plant, Rhode Island, US
US-based biopharmaceutical company Amgen is developing a bio-manufacturing facility at its campus in West Greenwich, Rhode Island, US.
Chugai Pharmaceutical’s New Synthetic Research Facility, Tokyo
Eisai Centre for Genetics Guided Dementia Discovery, Massachusetts, US
Minakem’s High-Containment Production Facility, Louvain-la-Neuve, Belgium
Boehringer Ingelheim Biologicals Development Centre (BDC), Biberach, Germany
Clinical Trials
Realm Therapeutics unveils phase II failure of PR022 for severe eczema
US-based Realm Therapeutics has announced its drug candidate PR022 for atopic dermatitis has failed to achieve its primary endpoint in a phase II trial.
Janssen and ViiV report positive results for two drug regimen for HIV-1
US FDA accepts the NDA for Motif Bio’s iclaprim for ABSSSI treatment
Seattle Children’s launches new CAR T-cell immunotherapy trial
Study shows methylphenidate is most effective ADHD drug for under-16s
Drug Development
Realm Therapeutics unveils phase II failure of PR022 for severe eczema
US-based Realm Therapeutics has announced its drug candidate PR022 for atopic dermatitis has failed to achieve its primary endpoint in a phase II trial.
Janssen and ViiV report positive results for two drug regimen for HIV-1
RXi and Karolinska Institutet target solid tumour therapy
US FDA accepts the NDA for Motif Bio’s iclaprim for ABSSSI treatment
Mustang Bio licenses gene therapy for bubble boy disease
Market Data
Study shows remifentanil better at relieving pain in labour than current standard care
An alternative opioid pain relief drug, remifentanil, can better relieve pain and reduces the need for an epidural for pregnant women during labour than the...
Deals this week: Pharmaxis, Almirall, Cipla Quality Chemical Industries
Spark Therapeutics Q2 financial results: income growth helped by US launch of Luxturna
Mylan Q2 financial results: revenue decline led by falling sales in North America
FDA approves Vertex’s cystic fibrosis therapy Orkambi for children under six
Technology
PhRMA survey shows US biopharma exceeded R&D spending record in 2017
Spending by members of the Pharmaceutical Research and Manufacturers of America (PhRMA) on research and development (R&D) set a new record by totalling $71.4bn in...
AI technology to help design personalised combination therapy
UNC develops artificial intelligence system to design new drugs
New UK Health Secretary lays out major priorities for the NHS
Roche and PureTech to develop oral antisense oligonucleotides